Evidence map›Paper›PMID 29774112›Full record

ArticleOncotarget2018

Rare genetic heterogeneity within single tumor discovered for the first time in colorectal liver metastases after liver resection.

Mylène Sebagh, Nelly Bosselut, Alexandre Dos Santos, Marc-Antoine Allard, Aldrick Ruiz, Raphaël Saffroy, Daniel Cherqui, Eric Vibert, Denis Castaing, René Adam and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Mylène SebaghAP-HP Hôpital Paul Brousse, Laboratoire d'Anatomie Pathologique, Villejuif, France.
Nelly BosselutInserm, Unité 1193, Université Paris-Saclay, Villejuif, France.
Alexandre Dos SantosInserm, Unité 1193, Université Paris-Saclay, Villejuif, France.
Marc-Antoine AllardInserm, Unité 1193, Université Paris-Saclay, Villejuif, France.
Aldrick RuizAP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Villejuif, France.
Raphaël SaffroyInserm, Unité 1193, Université Paris-Saclay, Villejuif, France.
Daniel CherquiInserm, Unité 1193, Université Paris-Saclay, Villejuif, France.
Eric VibertInserm, Unité 1193, Université Paris-Saclay, Villejuif, France.
Denis CastaingInserm, Unité 1193, Université Paris-Saclay, Villejuif, France.
René AdamUniv Paris-Sud, UMR-S 1193, Université Paris-Saclay, Villejuif, France.
Antonio Sa CunhaInserm, Unité 1193, Université Paris-Saclay, Villejuif, France.
Antoinette LemoineInserm, Unité 1193, Université Paris-Saclay, Villejuif, France.
Assistance Publique – Hôpitaux de Paris · FRHôpital Paul-Brousse · FRUniversité Paris-Saclay · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effective individualized treatment of patients with colorectal liver metastases (CLM) requires tumor genotyping, usually based on the analysis of one single sample per patient. Therapy failure may partially be explained by sampling errors and/or intratumoral genetic heterogeneity. We aimed to demonstrate intratumoral genetic heterogeneity in CLM and enable pathologists to select tumor tissue for genotyping. All the tumors of 86 patients who underwent liver resection for a single CLM were reviewed. Of the 86 patients, 66 patients received chemotherapy and 20 patients did not receive chemotherapy before liver resection. All the tumor areas sampled were analyzed for

Indexed as

colorectal liver metastasesintratumoral genetic heterogeneitymutationspathological response

Identifiers

PMID29774112
PMCPMC5955166
OpenAlexW2799633310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.